These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 37232836)

  • 1. Management and Prevention of Cellular-Therapy-Related Toxicity: Early and Late Complications.
    Mucha SR; Rajendram P
    Curr Oncol; 2023 May; 30(5):5003-5023. PubMed ID: 37232836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of CAR T-cell Related Toxicities: What did the Learning Curve Teach us so Far?
    Murthy HS; Yassine F; Iqbal M; Alotaibi S; Moustafa MA; Kharfan-Dabaja MA
    Hematol Oncol Stem Cell Ther; 2022 Nov; 15(3):100-111. PubMed ID: 36395496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art.
    Abramson JS; Lunning M; Palomba ML
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():446-453. PubMed ID: 31099671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicities associated with adoptive cellular therapies.
    Hansen DK; Dam M; Faramand RG
    Best Pract Res Clin Haematol; 2021 Sep; 34(3):101287. PubMed ID: 34625233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. INSPIRED Symposium Part 3: Prevention and Management of Pediatric Chimeric Antigen Receptor T Cell-Associated Emergent Toxicities.
    McNerney KO; Hsieh EM; Shalabi H; Epperly R; Wolters PL; Hill JA; Gardner R; Talleur AC; Shah NN; Rossoff J
    Transplant Cell Ther; 2024 Jan; 30(1):38-55. PubMed ID: 37821079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
    Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
    Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
    Brudno JN; Kochenderfer JN
    Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing the toxicities of CAR T-cell therapy.
    Neelapu SS
    Hematol Oncol; 2019 Jun; 37 Suppl 1():48-52. PubMed ID: 31187535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicities following CAR-T therapy for hematological malignancies.
    Hernani R; Benzaquén A; Solano C
    Cancer Treat Rev; 2022 Dec; 111():102479. PubMed ID: 36308910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Primer on Chimeric Antigen Receptor T-cell Therapy-related Toxicities for the Intensivist.
    Ong SY; Baird JH
    J Intensive Care Med; 2024 Oct; 39(10):929-938. PubMed ID: 37899577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities.
    Gutierrez C; Brown ART; Herr MM; Kadri SS; Hill B; Rajendram P; Duggal A; Turtle CJ; Patel K; Lin Y; May HP; Gallo de Moraes A; Maus MV; Frigault MJ; Brudno JN; Athale J; Shah NN; Kochenderfer JN; Dharshan A; Beitinjaneh A; Arias AS; McEvoy C; Mead E; Stephens RS; Nates JL; Neelapu SS; Pastores SM
    J Crit Care; 2020 Aug; 58():58-64. PubMed ID: 32361219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current understanding and management of CAR T cell-associated toxicities.
    Brudno JN; Kochenderfer JN
    Nat Rev Clin Oncol; 2024 Jul; 21(7):501-521. PubMed ID: 38769449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment.
    Gu T; Hu K; Si X; Hu Y; Huang H
    WIREs Mech Dis; 2022 Nov; 14(6):e1576. PubMed ID: 35871757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy.
    Sterner RC; Sterner RM
    Front Immunol; 2022; 13():879608. PubMed ID: 36081506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypogammaglobulinemia After Chimeric Antigen Receptor (CAR) T-Cell Therapy: Characteristics, Management, and Future Directions.
    Wat J; Barmettler S
    J Allergy Clin Immunol Pract; 2022 Feb; 10(2):460-466. PubMed ID: 34757064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of chimeric antigen receptor T-cells in lymphoma.
    Anderson JK; Mehta A
    Expert Rev Hematol; 2019 Jul; 12(7):551-561. PubMed ID: 31177852
    [No Abstract]   [Full Text] [Related]  

  • 17. Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies: A Practical Review.
    Strati P; Gregory T; Majhail NS; Jain N
    JCO Oncol Pract; 2023 Sep; 19(9):706-713. PubMed ID: 37406255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Toxicity after chimeric antigen receptor T-cell therapy : Overview and management of early and late onset side effects].
    Garcia Borrega J; Heindel K; Göreci Y; Warnke C; Onur OA; Kochanek M; Schub N; Ayuk F; Wichmann D; Böll B
    Internist (Berl); 2021 Jun; 62(6):611-619. PubMed ID: 34032877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Building safety into CAR-T therapy.
    Peters DT; Savoldo B; Grover NS
    Hum Vaccin Immunother; 2023 Dec; 19(3):2275457. PubMed ID: 37968136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy.
    Schubert ML; Schmitt M; Wang L; Ramos CA; Jordan K; Müller-Tidow C; Dreger P
    Ann Oncol; 2021 Jan; 32(1):34-48. PubMed ID: 33098993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.